AVM Biotechnology Announces Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients
AVM Biotechnology is excited to advance AVM0703 to the next dose level cohort of no-option lymphoma patients. The drug has been well-tolerated. SEATTLE, WA, UNITED STATES, April 7, 2021 /EINPresswire.com/ -- AVM Biotechnology announced today that the …